-
Ultimovacs ASA – Disclosure of voting rights of Extraordinary General Meeting
-
Ultimovacs announces Acceptance of Publication in ‘Frontiers in Immunology’ featuring positive results from Phase I trial evaluating UV1 in Non-Small Cell Lung Cancer
-
Ultimovacs ASA: Notice of Extraordinary General Meeting on 11 November 2020 – proposed changes to the Board of Directors
-
Ultimovacs Announces Updated Positive Results from Phase I Trial Evaluating Universal Cancer Vaccine, UV1, in Non-Small Cell Lung Cancer
-
Ultimovacs Announces Positive Topline Results from Phase I Combination Trial Evaluating Universal Cancer Vaccine, UV1, in Malignant Melanoma Patients
-
Ultimovacs ASA: Second quarter 2020 result presentation
-
Ultimovacs ASA Announces Completion of Patient Enrollment in Phase I Trial in Malignant Melanoma
-
Ultimovacs ASA: Invitation to second quarter 2020 results webcast presentation
-
Ultimovacs ASA Announces First Patient Dosed in the Phase II INITIUM Trial in Metastatic Malignant Melanoma
-
Ultimovacs ASA Announces First Patient Enrolled in the NIPU Phase II Clinical Trial Testing UV1 Against Mesothelioma
